Claims for Patent: 10,526,407
✉ Email this page to a colleague
Summary for Patent: 10,526,407
Title: | T cell receptors and immune therapy using the same |
Abstract: | The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention. |
Inventor(s): | Alten; Leonie (Tubingen, DE), Maurer; Dominik (Mossingen, DE), Walter; Steffen (Houston, TX), Bunk; Sebastian (Tubingen, DE) |
Assignee: | Immatics Biotechnologies GmbH (Tuebingen, DE) |
Application Number: | 16/035,300 |
Patent Claims: | 1. A method of treating an HLA-A*02-positive patient who has cancer, comprising administering to the patient a population of transformed CD8+ T cells expressing at
least one vector encoding a T cell receptor (TCR) on the cell surface, wherein the TCR comprises: a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 2, and a
CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 3 and a CDR1.beta. chain comprising the amino acid sequence of SEQ ID NO: 7, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3.beta. chain comprising
the amino acid sequence of SEQ ID NO: 9; or a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 13, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 14, and a CDR3.alpha. chain comprising the amino acid sequence
of SEQ ID NO: 15 and a CDR1.beta. chain comprising the amino acid sequence of SEQ ID NO: 19, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 20, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 21; or a
CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 25, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 26, and a CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 27 and a CDR1.beta. chain
comprising the amino acid sequence of SEQ ID NO: 31, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 32, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 33; and wherein the TCR binds to a peptide consisting
of the amino acid sequence of FLLDGSANV (SEQ ID NO: 58) in complex with HLA-A*02, wherein the cancer is a FLLDGSANV (SEQ ID NO: 58)/HLA-A*02 complex-positive cancer selected from the group consisting of gastrointestinal cancer, gastric cancer, breast
cancer, colorectal cancer, esophageal cancer, liver cancer, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, cholangiocellular carcinoma, gallbladder cancer, head and neck squamous cell carcinoma, uterine and endometrial
cancer, and urinary bladder cancer.
2. The method of claim 1, wherein the population of transformed cells are produced by a method comprising isolating a cell from a subject, transforming the cell with at least one vector encoding the TCR to produce a transformed cell, and expanding the transformed cell to produce the population of transformed cells. 3. The method of claim 2, wherein the subject is a healthy donor. 4. The method of claim 1, wherein the TCR comprises one of the following a chain/.beta. chain pairs: an .alpha. chain consisting of the amino acid sequences of SEQ ID NO: 6 and a .beta. chain consisting of the amino acid sequences of SEQ ID NO: 12; an .alpha. chain consisting of the amino acid sequences of SEQ ID NO: 18 and a .beta. chain consisting of the amino acid sequences of SEQ ID NO: 24; or .alpha. chain consisting of the amino acid sequences of SEQ ID NO: 30 and a .beta. chain consisting of the amino acid sequences of SEQ ID NO: 36. 5. The method of claim 1, wherein the population of transformed cells are administered in the form of a pharmaceutical composition. 6. The method of claim 5, wherein the pharmaceutical composition comprises a chemotherapeutic agent selected from the group consisting of asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, and vincristine. 7. The method of claim 1, wherein the cancer is gastrointestinal cancer or gastric cancer. 8. A method of eliciting an antigen-specific CD8+ cytotoxic T cell immune response in an HLA-A*02-positive patient who has cancer, comprising administering to the patient a population of transformed CD8+ T cells expressing at least one vector encoding a T cell receptor (TCR) on the cell surface, wherein the TCR comprises: a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 1, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 3 and a CDR1.beta. chain comprising the amino acid sequence of SEQ ID NO: 7, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 8, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 9; or a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 13, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 14, and a CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 15 and a CDR1.beta. chain comprising the amino acid sequence of SEQ ID NO: 19, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 20, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 21; or a CDR1.alpha. chain comprising the amino acid sequence of SEQ ID NO: 25, a CDR2.alpha. chain comprising the amino acid sequence of SEQ ID NO: 26, and a CDR3.alpha. chain comprising the amino acid sequence of SEQ ID NO: 27 and a CDR1.beta. chain comprising the amino acid sequence of SEQ ID NO: 31, a CDR2.beta. chain comprising the amino acid sequence of SEQ ID NO: 32, and a CDR3.beta. chain comprising the amino acid sequence of SEQ ID NO: 33; and wherein the TCR binds to a peptide consisting of the amino acid sequence of FLLDGSANV (SEQ ID NO: 58) in complex with HLA-A*02, wherein the cancer is a FLLDGSANV (SEQ ID NO: 58)/HLA-A*02 complex-positive cancer selected from the group consisting of gastrointestinal cancer, gastric cancer, breast cancer, colorectal cancer, esophageal cancer, liver cancer, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, cholangiocellular carcinoma, gallbladder cancer, head and neck squamous cell carcinoma, uterine and endometrial cancer, and urinary bladder cancer. 9. The method of claim 7, wherein the population of transformed cells are produced by a method comprising isolating a cell from a subject, transforming the cell with at least one vector encoding the TCR to produce a transformed cell, and expanding the transformed cell to produce the population of transformed cells. 10. The method of claim 8, wherein the subject is a healthy donor. 11. The method of claim 7, wherein the TCR comprises one of the following a chain/.beta. chain pairs: an .alpha. chain consisting of the amino acid sequences of SEQ ID NO: 6 and a .beta. chain consisting of the amino acid sequences of SEQ ID NO: 12; an .alpha. chain consisting of the amino acid sequences of SEQ ID NO: 18 and a .beta. chain consisting of the amino acid sequences of SEQ ID NO: 24; or .alpha. chain consisting of the amino acid sequences of SEQ ID NO: 30 and a .beta. chain consisting of the amino acid sequences of SEQ ID NO: 36. 12. The method of claim 7, wherein the population of transformed cells are administered in the form of a pharmaceutical composition. 13. The method of claim 11, wherein the pharmaceutical composition comprises a chemotherapeutic agent selected from the group consisting of asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, and vincristine. 14. The method of claim 1, wherein the TCR comprises a complementary determining region (CDR) 3.alpha. chain consists of one of the following CDR3.alpha. chain/CDR3.beta. chain pairs: a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 3 and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 9; a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 15 and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 21; or a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 27 and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 33. 15. The method of claim 7, wherein the TCR comprises a complementary determining region (CDR) 3.alpha. chain consists of one of the following CDR3.alpha. chain/CDR3.beta. chain pairs: a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 3 and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 9; a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 15 and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 21; or a CDR3.alpha. chain consisting of the amino acid sequence of SEQ ID NO: 27 and a CDR3.beta. chain consisting of the amino acid sequence of SEQ ID NO: 33. 16. The method of claim 1, wherein the TCR comprises: a CDR1.alpha. chain comprising SEQ ID NO: 1; a CDR2.alpha. chain comprising SEQ ID NO: 2; a CDR3.alpha. chain comprising SEQ ID NO: 3; a CDR1.beta. chain comprising SEQ ID NO: 7; a CDR2.beta. chain comprising SEQ ID NO: 8; and a CDR3.beta. chain comprising SEQ ID NO: 9. 17. The method of claim 7, wherein the TCR comprises: a CDR1.alpha. chain comprising SEQ ID NO: 1; a CDR2.alpha. chain comprising SEQ ID NO: 2; a CDR3.alpha. chain comprising SEQ ID NO: 3; a CDR1.beta. chain comprising SEQ ID NO: 7; a CDR2.beta. chain comprising SEQ ID NO: 8; and a CDR3.beta. chain comprising SEQ ID NO: 9. 18. The method of claim 1, wherein the TCR comprises: a CDR1.alpha. chain consisting of SEQ ID NO: 1; a CDR2.alpha. chain comprising of SEQ ID NO: 2; a CDR3.alpha. chain comprising SEQ ID NO: 3; a CDR1.beta. chain consisting of SEQ ID NO: 7; a CDR2.beta. chain consisting of SEQ ID NO: 8; and a CDR3.beta. chain comprising SEQ ID NO: 9. 19. The method of claim 7, wherein the TCR comprises: a CDR1.alpha. chain consisting of SEQ ID NO: 1; a CDR2.alpha. chain comprising of SEQ ID NO: 2; a CDR3.alpha. chain comprising SEQ ID NO: 3; a CDR1.beta. chain consisting of SEQ ID NO: 7; a CDR2.beta. chain consisting of SEQ ID NO: 8; and a CDR3.beta. chain comprising SEQ ID NO: 9. 20. The method of claim 17, wherein the TCR is a single chain TCR. 21. The method of claim 19, wherein the cancer is lung cancer. 22. The method of claim 18, wherein the TCR is a single chain TCR. 23. The method of claim 21, wherein the cancer is lung cancer. 24. The method of claim 17, wherein the TCR is a single chain TCR. |
Details for Patent 10,526,407
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2036-08-17 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2036-08-17 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2036-08-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.